secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001437749-22-020116
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AcelRx Q2 net income $70.7M on $84.1M debt gain; revenue $0.6M
--------------------------------------------------------------

- Net income of $70.7M ($0.48 diluted EPS) vs net loss of $9.9M in Q2 2021, driven by $84.1M gain on extinguishment of royalty monetization liability.
- Revenue $0.6M; commercial ex-DoD unit sales up 133% YoY; total DSUVIA units 10,600.
- Realigned cost structure reducing headcount ~40%, generating expected annual savings of $9M.
- Cash and short-term investments $27.9M as of June 30, 2022; 983 DSUVIA formulary approvals achieved.
- Niyad supply chain progress; targeting Emergency Use Authorization in 2023; DZUVEO EU launch on track for Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774922020116/0001437749-22-020116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774922020116/acrx20220810_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-020116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer